October 2023 in “Journal of the Endocrine Society” In this study, distinct androgen excess subtypes were identified in women with PCOS, with the adrenal androgen excess cluster showing significantly higher rates of insulin resistance and type 2 diabetes, suggesting 11-oxygenated androgens as potential drivers of metabolic risk.
February 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Finasteride treatment changes urine metabolites in male pattern baldness patients.
8 citations
,
March 2020 in “Metabolites” This study found differences in urinary androgen and estrogen concentrations between male pattern baldness patients treated with finasteride and healthy controls, suggesting potential biomarkers for post-finasteride syndrome.
March 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Finasteride treatment changes certain urine metabolites in male pattern baldness patients.
August 2021 in “Journal of The American Academy of Dermatology” This article discusses metabolomics in the context of finasteride treatment for male pattern baldness and reports no new clinical results.